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Planar cell polarityPolycystic kidney disease is the deﬁning condition of a group of common life-threatening genetic disorders
characterized by the bilateral formation and progressive expansion of renal cysts that lead to end stage kidney
disease. Although a large body of information has been acquired in the past years about the cellular functions
that characterize the cystic cells, the mechanisms triggering the cystogenic conversion are just starting to
emerge. Recent ﬁndings link defects in ciliary functions, planar cell polarity pathway, and centrosome
integrity in early cystic development. Many of the signals dysregulated during cystogenesis may converge on
the centrosome for its central function as a structural support for cilia formation and a coordinator of protein
trafﬁcking, polarity, and cell division. Here, we will discuss the contribution of proliferation, cilium and planar
cell polarity to the cystic signal and will analyze in particular the possible role that the basal bodies/
centrosomemay play in the cystogenetic mechanisms. This article is part of a Special Issue entitled: Polycystic
Kidney Disease.stic Kidney Disease.
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Hereditary cystic kidney diseases comprise a heterogeneous group
of monogenic disorders [1]. In some instances the bilateral develop-
ment of multiple ﬂuid-ﬁlled cysts in kidneys is part of a more complex
syndromic clinical manifestation, whereas in others it is a distinctive
feature of the disease and an important cause of end stage kidney
disease. We will focus on the latter disorders, hereafter referred to as
polycystic kidney disease.
Polycystic kidney disease is characterized by the hyperproliferation
of tubular epithelial cells, the alterations of their ﬂuid secretion
functions, and changes in the extracellular matrix deposition and
ﬁbrosis, all ofwhichprofoundly alter the organ architecture and impair
renal function. Autosomal dominant and autosomal recessive forms of
polycystic kidney disease have been recognized with an incidence of
1:800 and 1:20,000, respectively.
Autosomal dominant polycystic kidney disease (ADPKD) is caused
by the dysregulation of the PKD1 or PKD2 genes, which code for
polycystin-1 (PC1) and polycystin-2 (PC2), respectively. PC1 and PC2
may form a complex through the interaction of the respective
carboxyl termini, thus establishing reciprocal regulatory functions.
Consequently, regardless of the genotype, the clinical manifestations
of ADPKD largely overlap, with few notable exceptions: on average,
individuals with mutation in the PKD1 gene reach end stage kidneydisease 20 years earlier than patients carrying mutations in the PKD2
gene, and PKD2mutations result in more severe disease in males than
in females.
Autosomal recessive polycystic kidney disease (ARPKD) results
from mutations in the polycystic kidney and hepatic disease 1 gene
(PKHD1), encoding ﬁbrocystin/polyductin (FPC) [2,3]. ARPKD gener-
ally manifests earlier in life with the most severe cases resulting in
perinatal or neonatal death. In addition, collecting duct ectasia results
in cysts that remain connected with the nephrons of origin. Unlike
ADPKD, in which cysts are prevalent in the collecting ducts but may
develop everywhere along the nephron, in ARPKD cystogenesis is
restricted to the collecting ducts.
PC1 is a large integral membrane protein with receptor-like
structural characteristics [4], which undergoes a complex Notch-like
processing [5,6]. Abundant evidence supports the role of the PC1
carboxyl terminus in signaling mechanisms. The C terminal tail of PC1
contains phosphorylation sites for different tyrosine and serine/
threonine kinases [7] and a domain for the interaction with G proteins
and the activation of the JNK/AP1 pathway [8,9]. Importantly, in res-
ponse to changes in mechanical stimulation, the carboxyl terminal tail
undergoes regulated intramembrane proteolysis and translocates into
the nucleus to activate the AP1 pathway through a process negatively
regulated by PC2 [10].
PC2 is a Ca2+ regulated, non-selective cation channel that shares
sequence and structure similarities with the superfamily of transient
receptor potential channels [11–15]. PC2 is expressed predominantly
in the ER, but it is also found in the Golgi, the plasma membrane, and
on the cilium where with PC1, and likely FPC, it forms a mechano-
sensor complex that controls Ca2+ inﬂux in response to ﬂow [16,17].
1264 K. Lee et al. / Biochimica et Biophysica Acta 1812 (2011) 1263–1271On the plasma membrane, PC2 only partially co-localizes with PC1
and adhesion complexes, suggesting that it may function indepen-
dently as homodimer or participate in different complexes with other
members of the TRP family, thus expanding the functional character-
istics of these channels [16]. The loose interaction of PC2 with PC1 and
adhesion complexes may be important to confer PC2 more dynamic
mechanosensorial properties independent of or opposed to PC1. For
example, situs inversus, the phenotype with reversed orientation of
visceral organs, is associated with Pkd2 but not Pkd1 knockout mouse
models, indicating the independent mechanosensing function of PC2
in the nodal cilia [18]. In the case of stretch-activated ion channels PC1
and PC2 exert opposing effects with PC2 inhibiting channel opening
and PC1 reverting this suppression [19]. Though many aspects of the
regulation of PC2 function remain unclear, the growing evidence of its
multiple interactions with cytoskeleton organizing proteins supports
its Ca2+-dependent mechanosensorial role at different cellular com-
partments (for a comprehensive review, see references [15,20,21]).
Interestingly, the subcellular localization of PC1 at the cell adherens,
desmosomes, focal adhesions, and cilia provides the proximity with
cytoskeletal components, suggesting a possible role of PC1 in the
control of cytoskeleton rearrangement (Fig. 1) [22–25].
Similar to PC1, FPC undergoes a complex proteolytic process at the
ciliary membrane [26,27]. The large ectodomain is cleaved by a
proprotein convertase and remains tethered to the carboxyl stalk viaFig. 1. Subcellular localization of PC1, PC2, and FPC. (A) Polycystic proteins localize to multi
selective channel whose activity is essential during renal morphogenesis. In the kidney, the c
cilium is supported by nine doublets of microtubules that nucleate from the basal body,
(B) Following cilium resorption, pericentriolar material (PCM) organizes around the centr
cellular structure and are required for multiple cellular functions including spindle organizat
FPC are found to associate with the spindle microtubules during cell division. While the ciliar
the centrosome andmitotic spindle remains obscure. Similarly unclear is whether the localiza
rearrangement. N, nucleus; G, Golgi apparatus; ER, endoplasmic reticulum; CA, cell adherens
TJ, tight junction; mt, microtubules; mf, actin microﬁlaments; if, intermediate ﬁlaments; MD
pericentriolar matrix; cm, ciliary membrane; amt, astral microtubules; smt, spindle microtudisulﬁde bonds. Shedding of the ectodomain occurs concomitantly to
the regulated intramembrane proteolysis that releases the intracel-
lular cytoplasmic tail that then trafﬁcs to the nucleus or nucleolus.
This process appears to be dependent on intracellular Ca2+ release,
but it remains unknown whether a ligand or a mechanical change
triggers the shedding of the ectodomain [26]. Similarly, the possible
paracrine signaling function of the shed domain and the implication of
the nuclear translocation on gene regulation remain unclear, though
the Notch-like regulation and the ciliary localization of the process
suggest that it may be involved in the maintenance of nephron
architecture.
Excellent reviews have presented and discussed the characteristics
and functions of polycystic genes and their encoded proteins in detail
[28–31]. Here we will review the early events of renal cystogenesis
and the relationship of polycystic proteins with the centrosome, its
association with the cilium and its function in cell cycle control.
2. Proliferation of cystic cells
Cell hyperproliferation underlying continuous expansion of the
cysts and renal enlargement is a hallmark of ADPKD and ARPKD and a
determinant of renal failure [32,33]. Under normal conditions the
mitotic index of the adult kidney is very low. However, in renal tissues
from ADPKD or ARPKD patients, as well as from Pkd1 or Pkd2 mutantple compartments within the cell including the cilium in which they form a Ca2+ non-
ilium protrudes from the apical side of renal epithelial cells into the lumenal space. The
a specialization of the mother centriole (MC), at the base of the cilium (1A, inset).
ioles to form the centrosome. Microtubules emanating from the centrosome maintain
ion and cytokinesis. Polycystic proteins also localize to the centrosome and both PC2 and
y localization of polycystic proteins is important for ﬂuid ﬂow sensing, their function on
tion at cell–cell and cell–matrix contacts plays a role in tension sensing and cytoskeletal
; D, desmosomes; HD, hemidesmosomes; FA, focal adherens; ECM, extracellular matrix;
, mother centriole; DC, daughter centriole; TZ, transition zone; TF, transition ﬁber; PCM,
bules.
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(PCNA) and Ki67 mitotic markers are readily detectable [34–36]. In
fact, multiple mitogenic pathways may be constitutively activated in
polycystic kidney disease as a consequence of altered Ca2+ homeo-
stasis or abnormal protein trafﬁcking.
Defects in PC2 Ca2+ channel activity that lead to low intracellular
Ca2+ concentration, aberrant G-protein signaling by PC1 dysregula-
tion [8,37], and decreased cyclic nucleotide catabolism [38] may
contribute to the accumulation of cAMP and the abnormal activation
of the Ca2+ inhibitable adenyl cyclase 5/6. Cystic cells proliferate in
response to increased cAMP levels [39,40] and the activation of the
PKA/B-Raf/MAPK pathway [41], in contrast to normal primary renal
epithelial cells, whose growth is inhibited by cAMP [42]. Cyst expan-
sion then accelerates partly through a mechanism promoting chloride
-driven ﬂuid secretion [43,44].
Altered protein trafﬁcking may also contribute to cystogenic signals
as in the case of themislocalization of EGF receptors in renal epitelia. The
EGF receptor (EGFR/HER1) is normally expressed apically during the
embryonic mammalian kidney development, but its localization shifts
to the basal side in the adult organ. In ADPKD and ARPKD, however, the
EGFR/HER1 expression is increased and mislocalized to the apical
membrane where it results in a paracrine loop of persistent stimulation
by its ligand released in the ﬁltrate or in the cystic ﬂuid [45–47]. Other
dedifferentiating processes characteristic of cystic cells may further
reinforce this autostimulatory mechanism. For instance, the expression
of ErbB2/Neu/HER2, a member of the EGFR superfamily, is develop-
mentally regulated and restricted to the embryonic kidneys. However,
the re-expression ErbB2/Neu/HER2 in the adult ADPKD renal epithelia
allows it to heterodimerize with EGFR/HER1 on the apical membrane
[48]. The interference with the autocrine/paracrine EGF/EGFR stimula-
tory loop reduced cystic lesions in organ culture [49], slowed down cyst
expansion and ameliorated polycystic kidney disease in different,
though not all, animal models [50–53].
Other proliferative pathways may also be activated. In particular,
the evidence of the activation of the mammalian target of rapamycin
(mTOR) signaling in the cyst lining cells of the kidneys from different
mouse models of renal cystic disease (MAL, overexpressing myelin
and lymphocyte protein; and the IFT88 hypomorph, orpk) and in
human ADPKD specimens suggests that this may be a common
pathway underlying cystic proliferation [54] (for an extensive review,
see [55]).
The serine/threonine kinase mTOR is the key component of the
multiprotein complexes mTORC1, which positively controls protein
translation, cell metabolism and proliferation, and mTORC2, which is
involved in actin cytoskeleton organization and cell survival [56,57].
The activation of mTORC1 is suppressed by the heterodimer of ham-
artin and tuberin, encoded by the TSC1 and TSC2 genes, respectively.
Stimulation of the PI3kinase/Akt or ERK pathways leads to the
phosphorylation-mediated inhibition of TSC2/tuberin and the activa-
tion of mTORC1 [58,59]. Tuberin and PC1 functionally cooperate to
regulate the mTOR pathway. PC1 interacts with tuberin [54],
sequesters it on the membrane and protects it from Akt phosphor-
ylation, thus suppressing the activation of mTORC1 [60]. Conversely,
tuberin is necessary for the proper localization PC1, as seen in Eker
rats that carry a homozygousmutation of the Tsc2 gene. In the absence
of functional tuberin, PC1 accumulates in the Golgi and fails to pro-
perly trafﬁc to the lateral cell membrane, demonstrating that tuberin
is necessary for correct PC1 localization [61].
In various animal models of polycystic kidney disease, a signiﬁcant
reduction of cystic growth has been obtained by pharmacologically
preventing the cAMP increase, Ca2+ imbalance, EGF stimulation,
mTOR activation [62–67] or by inhibiting cell cycle progression with
the cyclin-dependent kinase inhibitor, roscovitine [68]. These in vivo
results have provided the rationale for different experimental thera-
peutic approaches that are currently under investigation [69]. How-
ever, recently concluded clinical trials that tested the efﬁcacy of mTORinhibitors (rapamycin/sirolimus and the analog everolimus) on
ADPKD patients at different stages of the disease yielded disappoint-
ing results. Treatment with these inhibitors showed no improvement
in the renal function, despite a transient reduction in total kidney
volume in patients with a more advanced stage of disease [70,71].
Unlike the ﬁndings from a shorter study with sirolimus on fewer
patients [72], these trials also indicated that both mTOR inhibitors
presented considerable side effects that severely limit their thera-
peutic value for ADPKD, even when administered at doses far lower
than those used in the animal models.
A further detailed analysis of these studiesmay help explain some of
the differences within the human studies and the discrepancies with
the experimental data on animal models as commented in references
[73,74]. In light of the remarkably promising preclinical results, it would
be premature to interpret the discouraging results of the human trials
to confute the validity of targeting themTORpathway in cystic diseases.
Rather, it may be necessary to explore alternative strategies in which
mTOR inhibition is part of a combination therapy or in which mTOR
inhibitors could be speciﬁcally targeted to the kidney.
A smaller clinical trial on ADPKD patients was also conducted to
assess the efﬁcacy of octreotide, a long-lasting somatostatin analog,
that inhibits the intracellular accumulation of cAMP in renal epithelia
[75]. In this 12-month study, results similar to those with mTOR inhi-
bitors were obtained: octreotide arrested the increase of kidney
volume but failed at improving kidney function. Differently from
mTOR inhibitors, however, octreotide appeared to be well tolerated
with no serious adverse effects.
Overall, these clinical trials underscore the complexity and
variability of the disease progression, and question the use of kidney
volume change as a surrogate marker of organ function [32,33,73].
They also suggest that at advanced stages of the disease, cell
proliferation is dissociated from cellular and organ function. As
such, proliferation may have different roles at different stages of
cystogenesis. Findings of proliferating cells in normal tubular epithelia
surrounding cysts suggest that cell growth is an early event in the
cystogenic transformation. Nevertheless, no cysts derive from the
active proliferation during normal organ morphogenesis, and active
growth of renal carcinoma cells does not necessarily result in cyst
formation. Therefore, it remains difﬁcult to establish whether the
activation of these pathways represents the cystogenic trigger or if it
supports cyst expansion.
3. Cilium and cystogenesis
The observation that cystic proteins localize on the primary cilium
and basal body [76–78] provided new insights into themechanisms of
renal cystic diseases. The intense focus on the cilium that followed
unveiled the genetic determinants of numerous complex diseases that
deﬁne a new class of disorders collectively referred to as ciliopathies
(for comprehensive reviews, see references [79–82]).
The primary cilium is a highly compartmentalized organelle pre-
sent in most cell types that functions as a sensor of extracellular
environmental cues. It is formed as a single protrusion of the plasma
membrane supported by the axoneme, a cytoskeletal component that
is assembled as a ring of 9 microtubule doublets arranged tangen-
tially to the center in a conﬁguration known as 9+0 (Fig. 1A, inset).
Defects in cilia formation result in complex phenotypes, which
invariably include cystic kidneys [83]. In renal epithelia, cilia convert
mechanical force of ﬂuid ﬂow into cellular functions [84]. PC1, PC2 and
FPC are expressed in renal primary cilia where they are a part of a
mechanosensor complex that translates the ciliary bending induced by
ﬂow into Ca2+ inﬂux [85–87]. Their functional role was supported by
observation that STAT6, whose ciliary localization depends on ﬂow
stimulation, is part of a complex that includes the cleaved carboxyl
terminus of PC1 and the transcriptional coactivator P100. As the
carboxyl tail of PC1 is proteolytically cleaved, the complex translocates
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mechanical stimulation of the cilium by urine ﬂow and cellular res-
ponses [88]. However, impaired mechanosensation of cilium as a
primary defect in cystogenesis was challenged by the work on
conditional knockout models of the intraﬂagellar transport Ift88
(polaris) and the Kif3a subunit of kinesin-2 genes, which are essential
for ciliogenesis [89]. While the deletion of Ift88 or Kif3a during
gestation prevented cilia formation and resulted in severe cystic
disease within 2 weeks after birth, deletion of either gene in the adult
animals did not immediately result in detectable cystic phenotype,
despite the cilia ablation. Eventually, mild renal cyst formation was
observed 6 months after the knockout, revealing different require-
ments of ciliary function during renal development and in the
maintenance of adult kidney [89]. These results indicated that cilia
are dispensable in adult mice and that other components may par-
ticipate in the cystic process.
Interestingly, the conditional models of Pkd1 inactivation similarly
displayed greater susceptibility of youngmice to develop severe cystic
kidney disease as compared to the adult mice. These mouse models
offered the opportunity to investigate the early cystogenetic events
following the depletion of PC1 [90–92]. A detailed analysis of perinatal
Pkd1 inactivation demonstrated that the deletion of the gene within
day P13 led to extensive cystogenesis and kidney enlargement,
whereas inactivation of Pkd1 from day P14 onward resulted in late
onset cystic kidney disease [91]. These observations uncovered a
window of susceptibility, which corresponds with the completion of
mouse nephrogenesis when proliferation is actively ongoing and a
speciﬁcally timed brake point. However, the study also showed that
although proliferation abruptly decreased after day P14, it remained
signiﬁcantly higher at P16 as compared to the adult kidney. Never-
theless the course of cystic disease was comparable in the P16 and
oldermice, suggesting that proliferation per semay not be sufﬁcient to
trigger the cystogenic change [91]. As the brake point was character-
ized molecularly by a change in gene expression pattern consistent
with a developmental switch, it was proposed that components of an
early developmental program could in fact be the cystogenic triggers.
Such a program may be recalled during the re-epithelization process
that follows renal injury. In support of this notion, in adult kidneys in
which Pkd1 is conditionally inactivated or in which no cilia can be
formed because of the conditional Kif3a excision, the cystic phenotype
can be accelerated by the induction of ischemia/reperfusion injury or
pharmacological nephrotoxicity [36,93,94]. In addition, although cell
growth occurs rapidly following injury, it reverts to control levels
before cystic expansion, again suggesting that proliferation cannot be
the only cystogenic switch [94]. Nevertheless, even though prolifer-
ation may not be sufﬁcient as the sole cystogenic trigger, it may yet
provide the necessary context for such a trigger to arise as indicated in
recent experiments on the conditional inactivation of the Hnf1b gene,
which encodes a transcription factor involved in the expression of
genes that include Pkd2, Pkhd1 and UMOD (encoding uromodulin).
Similar to the IFT88, Kif3a, and Pkd1 models, the pre- or perinatal
conditional inactivation of Hnf1b leads to rapid polycystic kidney
disease, while the ablation of Hfn1b in the adult leads to slow onset
cystic disease that can turn into rapidly progressing disease following
renal injury. Careful analysis of proliferating cells using BrdU showed
that tubular dilatation coincided with the regenerative proliferation
burst and the loss of mitotic orientation only in the mutant dividing
cells and not in those of wild type kidneys [95]. Therefore, cell
proliferation may create the conditions for the cystogenic switch,
which may include defects in oriented cell division, planar cell
polarity (PCP), and changes in the centrosome positioning [93–95].
4. Role of planar cell polarity in cystogenesis
The organization and asymmetric distribution of protein content
that cells maintain in parallel to the epithelial plane is called planarcell polarity (PCP). The mechanisms of PCP are fundamental for the
developmental patterning of both invertebrates and vertebrates [96]
and are regulated by the non-canonical Wnt pathway (for a compre-
hensive review of the Wnt signaling in cystic diseases, see reference
[97]).
During kidney development, the spindle of the dividing cell
organizes with an orientation parallel to the axis of the elongating
tubule, revealing an intrinsic cell polarity. The evidence of a link
between cilia and PCP came from the observation that the ciliary
protein inversin, the product of the NPHP2 gene whose mutations
cause nephronophtisis, functioned as a switch from the canonical to
the non-canonical Wnt pathway [98]. Whether PCP in turn played a
role in cystic disease was ﬁrst observed in kidneys in two rodent renal
cystic models: the mouse with inactivation of the Tcf2/HNF1β trans-
cription factor [99], and the pck rat, which carries a mutated PKHD1
gene ortholog [100]. In both cystic models a signiﬁcant number of
spindles in the dividing cells of the kidneys were misaligned, sug-
gesting that the loss of proper spindle orientation and planar cell
polarity are linked to cystogenesis [101].
Recently, a direct proof of the role of PCP in renal cystic deve-
lopment was provided by the knockout mouse model of Fat4 gene,
which encodes a PCP protein of the proto-cadherins family [102].
Homozygous Fat4−/− mutants died at birth but displayed multiple
characteristics of PCP protein defects including anomalies in the
elongation of the cochlea and disruption of hair cell organization in
the organ of Corti. Fat4−/− mutants also displayed smaller kidneys
with dilated and shorter tubules and signiﬁcant defects in oriented
cell division. Crossing Fat4−/− mice with mutants for other PCP
components, Vangl2 and Fjx1, exacerbated the cystic phenotype [102].
Together with the ciliary localization of FAT4, these ﬁndings further
strengthened the link between PCP and cilium during cystogenesis.
The interdependence of PCP and ciliary function is also supported by
observations with other PCP core proteins, Dishevelled and Vangl2.
Dishevelled is involved in the docking of the centrioles/basal bodies to
the apical membrane that precedes ciliogenesis [103], and Vangl2 is
required for the asymmetric positioning of motile cilia in cells of
zebraﬁsh neural tube [104]. Furthermore, the ﬂuid ﬂow inﬂuences
centrioles' movement and contributes to the orientation of motile cilia
in conjunction with PCP in ependymal cells [105,106].
It should be noted, however, that more recent reports question the
role of oriented cell division as a primary cause of cystogenesis. In the
hypomorphic mutant for Wnt9b, whose expression is required for
renal morphogenesis, cystogenesis starts in utero, leading to the
development of grossly cystic kidneys within a month of age [107].
The analysis of the embryonic renal development revealed that during
the period from E13.5 to P1, tubules lengthen through the movement
of the cells that assume an elongated shape parallel to the tubule axis
in a process of convergent extension, which is dependent on PCP and
the activation of the Rho/Jnk signaling pathway. The impairment of
this process in theWnt9bmutants alters tubule diameter and triggers
cyst formation. Interestingly, until P1, cell division appeared similarly
misoriented in both Wnt9b mutants and wild type mice, suggesting
that defects in oriented cell division alone cannot account for in utero
cystogenesis [107]. Moreover, a study in Pkd1, Pkd2 and Phkd1mouse
mutants showed that changes in oriented cell division did not precede
cystogenesis, but rather followed the cystic transformation [108].
While challenging the defects of oriented cell division as a driver of
cystogenesis, these results nevertheless emphasize the role of PCP in
cystogenesis.
5. Centrosome and cell cycle
The basal bodies located at the base of the cilium are a mor-
phological specialization of the centrioles/centrosome, speciﬁcally the
mother centriole from which the axoneme emanates to support the
formation of the primary cilium (Fig. 1). Functionally, the basal bodies
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tion of the transition zone and the control of vesicles trafﬁcking to and
from the cilium [109], thereby coupling the cilium and centrosome
functions. The essential role played by the centrosome in coordinating
the ciliary and PCP crosstalk is further emphasized by the alteration of
theWnt signaling following the disruption of basal bodies in zebraﬁsh
bbs4 morphants [110].
The centrioles/centrosome serve as the microtubule-organizing
center (MTOC), and thus play a major role in the spatial organization
of the microtubular network required for not only the formation of
primary cilia, but also cell polarity, migration, trafﬁcking of cytoplas-
mic organelles, and organization of the mitotic spindle [111]. Because
of these essential functions that it underlies, the centrosome integrity
and duplication are tightly controlled. In most cells, under normal
conditions the centrosome divides only once per cell cycle through a
mechanism coupled to the cell cycle progression, so that each daugh-
ter cell receives only one centrosome [112,113]. Reciprocal interac-
tions exist between IFT and centrosomal proteins to regulate their
trafﬁcking and localization. For example, IFT20 shuttles between the
Golgi and the cilium, and is required for the localization of pericentrin
to the centrosome [114,115]. Conversely, reduced expression of
pericentrin also lowers the levels of IFT20, IFT88, IFT57 and PC2 in
centrioles and inhibits cilia formation [115].
In cells preparing to cycle, the cilium is reabsorbed, leaving the
basal bodies/centrioles free to anchor to the cell cortex and to be ready
for centrosome duplication and the subsequent organization of the
microtubule rearrangement that is required for the assembly of the
spindle, mitosis, and cytokinesis. Cilium resorption may allow
redistribution of ciliary components to the centrosome that can affect
the cell cycle progression. For instance, IFT88/polaris remains tightly
associated with the centrosome andmodulates the G1–S transition by
titering out Che-1, an inhibitor of the growth suppressor function of
Rb [116]. Consequently, interfering with various centrosome proteins
leads to the p53-dependent block of cell cycle progression from G1 to
S and failure to assemble cilia [117,118]. p53 is also a centrosomal
protein, and its depletion increases centrosome ampliﬁcation [119].
The control of cell cycle progression and restriction of centrosome
overduplication by p53 is exerted partly via the transactivation of p21
and the direct association of p53 with the centrosome [120–122].
Both PC1 and PC2 exert a direct effect on cell cycle and centrosome
duplication. The heterologous expression of PC1 or PC2 arrests the
cell cycle in G1 through different mechanisms that converge on the
induction of the cyclin-dependent kinase (Cdk) inhibitor p21 and the
inhibition of Cdk2 activity [123,124]. In the case of PC1, the expression
of p21 results from the activation of the JAK2-dependent phosphor-
ylation of STAT1, but not of p53 [123]. In contrast, PC2 functions by
binding to Id2, a member of the helix–loop–helix (HLH) family of
transcriptional regulators that antagonize basic HLH transcription
factors that are involved in the control of cell cycle progression. The
interaction with PC2 sequesters Id2 in the cytosol, thus preventing its
translocation into the nucleus where it suppresses p21 transcription
[124]. PC1 and PC2 exert a reciprocal control on the activation of these
pathways. The physical interaction of PC1 with JAK2 is dependent on
the presence of PC2 as a cofactor, whereas PC1 phosphorylation of PC2
is required for its interaction with Id2. Conversely, depletion of PC1 or
PC2 results in faster G1 to S progression [124–126] and reduced
expression of p53 in HEK293 cells [125]. Lowered p53 expression is
also observed in embryonic kidneys of Pkd1−/−mice [127], albeit in
this case it is difﬁcult to determinewhether such downregulation is an
effector or a consequence of the cystogenic transformation.
Polycystic proteins localize on the centrosome and are important
to maintain centrosome integrity (Fig. 2). The inhibition of PC1
expression induces centrosome ampliﬁcation in vitro, and supernu-
merary centrosomes were observed both in the kidneys of Pkd1 con-
ditional knockout animal model and in human renal tissue from
ADPKD patients in vivo [128]. These centrosomes appeared fullyfunctional, as they were able to organize multipolar spindles. How-
ever, the cells dividing with aberrant mitotic spindles entered mitotic
catastrophe or produced genetically unstable progeny, characterized
by signiﬁcant apoptosis and aneuploidy [129,130]. Ampliﬁed centro-
somes were noted on seemingly normal tubular cells, suggesting that
centrosome aberrationsmay be an early event in the cystic conversion
[128]. Similarly, centrosome ampliﬁcation was also reported in ﬁbro-
blast cell lines derived from Pkd2 transgenic mice and in mesenchy-
mal cells of Pkd2 knockout embryos [131], indicating that PC2 dys-
regulation also affects centrosome integrity. Polycystins' broad tissue
distribution and the effects of interference of PC1 or PC2 in cen-
trosome integrity in non-renal cells suggest that polycystins play a
fundamental role in the mechanisms controlling centrosome dupli-
cation and that centrosomal aberrations may be important in cystic
development.
More recently, at least some FPC isoforms have also been shown to
be required for the maintenance of centrosome integrity and proper
spindle assembly [132]. Similarly to PC2, FPC is found on the spindle
during cell division, but the mechanisms controlling its localization
remain unknown. The spindle localization of PC2, however, was
shown to require the interaction with Diaphanous (mDia)-related
formin 1, mDia1 [133], a protein involved in actin polymerization and
microtubule stabilization [134]. Depletion of mDia1 coincides with
the loss of PC2 localization from the spindle and a decreased Ca2+
release in mitotic cells. The function of PC2 on the spindle is unclear,
but the interaction of PC2 with the actin bundling protein α-actinin
and with the microtubule-dependent motor kinesin-2 subunit KIF3A,
both of which activate PC2 channel activity in vitro, lends support to
the intriguing possibility that PC2-mediated Ca2+ transport may
function in the cytoskeletal remodeling required for cell division
[21,135,136]. Although the spindle localization of PC1 is unclear, its
presence on the centrosome along with FPC may be important in
the reconstitution and regulation of the PC2 Ca2+ channel activity
[87,132,137]. Overall, these observations underline the interdepen-
dence of cilium, centrosome, and cytoskeletal rearrangement.
The mechanisms contributing to centrosome ampliﬁcation remain
speculative, but it might involve the altered expression of p53 and/
or cyclin-A, as observed in PC1-deﬁcient cells [125,138], as well as
imbalanced Ca2+ homeostasis. Centrosome ampliﬁcation can occur
following cytokinesis failure or by reiterated centriole duplication
within the same cycle. Evidence of multinucleation and enlarged
nuclei in PC1- or PC2-deﬁcient cells suggests that supernumerary
centrosomes may result from endoreduplication. Cytokinesis depends
on the accumulation of Ca2+ stores to the furrow and on the proper
Ca2+ release before abscission [139]. It remains to be determined
whether the reciprocal interaction of PC2 (or a polycystins complex)
with cytoskeletal components has any function on this Ca2+ regu-
lation. Furthermore, both centrosome duplication and cell growth
processes depend on increased Ca2+ transients from internal Ca2+
stores [140], a requirement that seems to be at odds with the
decreased intracellular Ca2+ content in polycystic cells [141,142].
However, experiments on HEK293 cells indicate that PC1 negatively
regulates non-capacitative Ca2+ entry (NCCE) channels and that cell
proliferation upon PC1 knockdown is sustained by an NCCE-
dependent increase in Ca2+ oscillations [143]. Hence, it is possible
that changes in the frequency and amplitude of Ca2+ oscillations may
support also centrosomal ampliﬁcation or centriole reduplication
[144].
The centrosomal defects extend to other diseases with renal cystic
manifestations. Loss of hamartin, the product of the TSC1 gene whose
mutations cause tuberosclerosis, also leads to centrosome ampliﬁca-
tion [145]. The depletion of the centrosomal Mks1 or Mks3/meckelin
proteins, which are mutated in the autosomal recessive Meckel-
Gruber syndrome, results in centrosome ampliﬁcation and, in the case
of Mks3, in multiciliation [146]. Renal cysts develop following the loss
of IFT20, which results in cilia ablation, centrosome ampliﬁcation with
Fig. 2. Centrosome ampliﬁcation following the suppression PC1 or PC2 expression. Centrosome ampliﬁcation andmitotic spindle abnormalities occur rapidly after the knockdown of
Pkd1 or Pkd2. Shown are MDCK cells and IMCD3 cells 3 days following the transduction with a lentivirus constitutively expressing the shRNAs speciﬁc for Pkd1 and Pkd2,
respectively. IMCD3 cells (or MDKC cells, not shown) transduced with control lentivector expressing shLuc against luciferase (siLuc) maintain normal mitosis. Cells were
immunostained with anti-α-tubulin and anti-γ-tubulin to speciﬁcally detect microtubules (green) and centrosomes (red), respectively, and then counterstained with DAPI to
visualize DNA (blue).
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[147]. It will be of interest to determine whether centrosome defects
are common to other renal cystic diseases.
Centrosome aberrations occur early after the inhibition of poly-
cystic proteins and, similar to ciliary defects, they may be a common
denominator in renal cystic disease. A causative role of centrosome
defects in cystogenesis is difﬁcult to establish, but its expected conse-
quences are consistent with all the ﬁndings characteristic of ADPKD
cells. Errors in centrosome duplication may result in the formation
of monopolar or multipolar spindles, aberrations associated with
chromosomemissegregation, genomic instability, and apoptosis. Cells
that accumulate excessive genomic damage/imbalance become
apoptotic, whereas others may survive carrying abnormal karyotypes
[148,149], and altered physiological functions. A kidney-speciﬁc
interference with effectors of the centrosome duplication process
will be required to establish a causal link between centrosome ano-
malies and renal cystic development.
6. Conclusions
As intense research has focused on cystic cells, we have a better
understanding of the mechanisms that support cystic expansion,
including alterations of calcium homeostasis and changes in protein
trafﬁcking and interactions, which sustain the constitutive activation
of mitogenic pathways. On the other hand, the signals (or lack there-
of) that trigger the cystic conversion are unknown and the mecha-
nisms underlying the early cystogenic events are just emerging in a
picture of increasing complexity.
The view of the cilium as sensor of ﬂuid ﬂow has expanded to
the regulation of planar cell polarity and defects in PCP-controlled
mechanisms, convergent extension, and oriented cell division
have been indicated as possible cystogenic triggers. However, it
seems that ciliary functions and PCP in the cystogenic conversioncannot be clearly separated, as they exert a reciprocal regulation.
Docking of centrioles/centrosome to the cortex is essential for the
formation of the basal bodies and ciliogenesis as well as for the
establishment of the spindle pole position [150]. Therefore, a cysto-
genic trigger driven by centrosome ampliﬁcation is also conceivable
as the presence of supernumerary centrioles, caused by the depletion
or malfunction of different cystic proteins, can produce conﬂicting
cues leading to improper attachment, misalignment of the spindle
axis, or altered cilium positioning. These effects may be exposed by
the dysregulation of cell cycle progression in cells with ampliﬁed
centrosomes.
Very important has been the ﬁnding that a developmental switch
limits the cystogenic susceptibility to ciliary defects to a period of time
largely overlapping with the completion of murine renal morpho-
genesis [91]. Whether PCP mutants are similarly constrained remains
to be demonstrated, and experiments with conditional inactivation of
PCP genes may provide a clue on whether and how ciliary and PCP
functions follow an order of succession in cystogenesis. In the adult,
tubular epithelia injury reestablishes the susceptibility to cystogen-
esis, although it has not been determinedwhether this depends on the
reactivation of the same renal morphogenetic developmental pro-
gram. Both early development and repair processes are characterized
by the need for cell proliferation. Since proliferation shows a biphasic
curve, that is, it subsides before starting again in the cystic cells, it
cannot be the main cystogenic trigger [94]. Nevertheless, proliferation
appears necessary for the trigger to be set off [95].
While we are gaining a better understanding of multiple cellular
processes and cell components that play a role in cystogenesis, a
unifying pathogenetic mechanism is still missing, largely due to our
incomplete knowledge of the workings of polycystic proteins. Further
efforts will be necessary to integrate the functions of cilium/
centrosome, PCP, and cell proliferation and to determine the sequence
of early events that initiate the cystogenic signal.
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